ASCL1 and prostate cancer: SOX2 itself stands as critical promoter of lineage plasticity and androgen resistance in TP53- and RB1-deficient prostate cancer; it reprograms transcriptional circuits in favour of a pro-neuronal specific gene expression pattern, which includes accumulation of ASCL1-positive neural progenitors and DCX-positive neuroblasts, both events known from SOX2-mediated adult neurogenesis in the brain [146,168,169].